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Donor Diabetes and Prolonged Cold Ischemia
Time Synergistically Increase the Risk of Graft
Failure After Liver Transplantation
Isabel M.A. Brüggenwirth, MSc,1,2 Natasha H. Dolgin, PhD,1,3 Robert J. Porte, MD, PhD,2 Adel Bozorgzadeh, MD,1
and Paulo N.A. Martins, MD, PhD1
Background.Both prolonged cold ischemia time (CIT) and donor history of diabetes mellitus (DM) are associated with reduced
graft survival after liver transplantation. However, it is unknownwhether the adverse effect of prolonged CITon posttransplant graft
survival is more pronounced after transplant with DM versus non-DM donor grafts.Methods.The study sample included 58 226
liver transplant recipients (2002-2015) from the Scientific Registry of Transplant Recipients. Multivariable Cox survival regression
with interaction analysis was used to quantify the extent to which history of donor DM (n = 6478) potentiates the adverse effect
of prolonged (≥8 hours) CIT (n = 18 287) on graft survival. Results. Donor DM and CIT 8 hours or longer were each associated
with increased risk of graft failure (GF) (adjusted hazard ratio [aHR], 1.19; 95% confidence interval [CI], 1.06-1.35 and aHR, 1.42;
95%CI, 1.32-1.53, respectively) comparedwith transplanted grafts without either risk factor. However, the combination of DM and
CIT 8 hours or longer was associated with a higher risk of GF than either factor alone (aHR, 1.79; 95% CI, 1.55-2.06) and had a
synergy index of 1.30. The interaction was significant on a multiplicative scale in the later postoperative period, days 31 to 365
(P = 0.047). Conclusions. These results suggest that liver grafts from DM donors are more susceptible to the adverse effects
of prolonged CIT than livers from non-DM donors. We need to be cognizant that they are more susceptible to ischemic injury, and
this may be considered during the allocation process.
(Transplantation Direct 2017;3: e173; doi: 10.1097/TXD.0000000000000692. Published online 12 June, 2017.)
L iver transplantation (LT) provides an effective treatmentfor patients with end-stage liver disease. Due to persis-
tent organ shortages, approximately 2000 patients die while
on the liver waiting list every year.1 To overcome this gap,
there has been an increase in the use of organs from deceased
donors that have multiple comorbidities and other factors
that are associated with increased risk of graft failure (GF).
The prevalence of diabetes mellitus (DM) amongUS adults
in 2011 was 23.7 million and this number is expected to in-
crease to 29.6 million in 2030.2 Only few studies regarding
the effect of donor DM on the risk of GF have been carried
out.3,4 It has been suggested that DM in donor livers may
be associated with adverse outcomes posttransplant.3 DM
often results in systemic vascular damage (diabetic microan-
giopathy)5 and is a risk factor for chronic hepatic injury
due to nonalcoholic fatty liver disease and subsequent pro-
gression to more advanced liver diseases.6
Prolonged cold ischemia time (CIT) is a well-established
risk factor for GF. Ischemic injury damages the liver graft at
the cellular level and may lead to primary nonfunction, delayed
graft function, and ischemic cholangiopathy.7 Ischemia-
reperfusion injury (IRI) is associated with the release of reactive
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oxygen species and proinflammatory mediators, which causes
damage of the hepatic sinusoidal epithelium and severe hepatic
microcirculatory impairment.8
We hypothesized that prolonged cold ischemia aggravates
preexisting microvascular changes that are seen in diabetic
donors grafts, leading to inferior graft survival. We explored
this question using over a decade of comprehensive US Trans-
plant Registry data and quantified the extent to which the effects
of donor DM on risk of GF 1 year post-LT are modified by
prolonged CIT.
MATERIALS AND METHODS
Study Design
This retrospective cohort study includes subjects that
underwent first LT between April 1, 2002, and April 1, 2015,
using Scientific Registry of Transplant Recipients (SRTR) data
(Figure 1). Exclusion criteria included: recipient age, younger
than 18 years (n = 6562), multiorgan (n = 4801) or living
donor (n = 2823) transplants, and patients with missing
or extreme values (>18 hours for CIT) on key predictor
variables, donor DM (n = 306) and CIT (n = 3391).
Retransplants were also excluded from analysis.
The primary study endpoint was 1-year GF, defined as
time to all-cause GF or retransplant. 1-month and 3-year
GF were included as secondary outcomes to investigate po-
tential early, and long-term consequences of IRI. Separate
survival models were fit for 1-year and 3-year results with ap-
propriate censoring as each person either died or was lost to
follow up. The primary exposure variables were prolonged
CIT (≥8 hours) and history of donor DM (DM+) versus no
DM (DM−). CITwas evaluated as a potential effect measure
modifier of donor DM on graft survival rate. CIT threshold
was dichotomized into CIT 8 hours or longer versus CIT less
than 8 hours based on previous publications.3 Sensitivity
analyses were done for CIT of 6, 8, and 10 hours as well as
using up to 5 categories of CIT. The results were not pre-
sented in the final analyses, because they did not meaning-
fully change the results.
Potential confounders included both donor and recipient
factors and were identified based on established clinical evi-
dence and literature review.3,4,9 Recipient characteristics
were collected perioperatively pretransplant and included
age, sex, race/ethnicity, body mass index (BMI), history of di-
abetes, last laboratory Model for End-Stage Liver Disease
(MELD) score, United Network for Organ Sharing (UNOS)
Status 1, primary liver diagnosis, hepatitis C status, Child-
Pugh score (and individual components albumin, bilirubin,
encephalopathy, and ascites), medical condition (intensive
care unit, hospitalized, or home) and whether patients were
receiving ventilatory support. Donor characteristics included
Donor Risk Index and its components (age, race/ethnicity,
FIGURE 1. Study Inclusion/exclusion criteria flowchart. Scientific
Registry of Transplant Recipients. a Retransplants were not included
in analyses. b Percent = N remaining / N starting sample.
c Extreme values
(>18 hours) change to missing.
TABLE 1.
Recipient pretransplant characteristics by donor DM status
Donor diabetes No donor diabetes
Characteristicsa (n = 6478) (n = 51 748) P
Age, y 55.1 ± 9.6 53.9 ± 10.1 <0.001
Women 29.6 32.7 <0.001
Race/ethnicity
White 72.2 72.2
Hispanic 12.8 12.8
African American 9.5 9.2
Other 5.5 5.8 0.78
BMIb
< 18.5 1.6 1.8
18.5 to < 25 25.9 27.0
25 to < 30 33.5 34.3
≥ 30 36.0 33.5 0.001
Diabetes 24.7 22.7 <0.001
Primary liver diagnosis
Noncholestatic 63.6 64.2
Cholestatic 7.4 7.8
Malignancy 20.3 17.9
Acute hepatic necrosis 4.0 4.9
Other 4.7 5.2
Hepatitis C 39.3 42.1 <0.001
UNOS status 1 2.1 3.0 <0.001
MELD (last laboratory)
< 15 32.9 30.1
15-29 48.6 47.6
30-34 7.9 8.7
35-40 10.6 13.6 <0.001
Albumin 3.0 ± 0.7 3.0 ± 0.7 0.65
Medical condition
Home 74.5 71.0
Hospitalized 15.9 17.2
ICU 9.7 11.8 <0.001
Ventilatory support 3.8 5.1 <0.001
SRTR 2002-2015 (N = 58 226).
a Mean ± standard deviation or column percentage (variables with missing data may not add up
to 100%).
b <18.5: underweight; 18.5-25: normal; 25-30: overweight; ≥30: obese.
ICU, intensive care unit.
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cause of death, donation after cardiac death, partial/split liver,
height, allocation type), sex, BMI, and history of hypertension.
Statistical Analyses
Variables were assessed for missingness and extreme
values; variables with more than 5% missing values were
not included in tables or regression analyses. A full list of var-
iables in the SRTR database can be found on the associated
website.10 Complete-case analyses were conducted, whereas
only subjects with complete data on all variables included
in the statistical equation were included in the models. We
evaluated the relationships between potential confounders
and the primary exposure variable using t tests for continu-
ous variables and χ2 tests for categorical variables. Results
are expressed as mean ± SD unless otherwise indicated.
Graft survival rates were estimated and tested using the
Kaplan-Meier method and log-rank tests, respectively. Cox
proportional hazards survival regression was used to exam-
ine the relationships between the primary predictors of inter-
est and graft survival. Multivariable models were built for
each predictor (donor DM, CIT) separately and then in com-
bination using a forward (manual) approach, sequentially
adding conceptually meaningful groups of variables while
assessingmodel fit. Only variables thatwere statistically signif-
icant were retained in the final model. Model goodness-of-fit
and proportional hazards assumptions were assessed graphi-
cally and confirmedwith the Grønnesby and Borgan test using
martingale residuals.11
Effect measure modification was assessed by evaluating
departures from additivity using dummy variables for each
possible combination of DM and CIT (short CIT, DM- (referent
group) / short CIT,DM+ / prolongedCIT, DM- / prolongedCIT,
DM+) and multiplicative effects were assessed using a product
term (interaction) for DM x CIT.
Results are expressed as hazard ratios (HR) (95% confi-
dence intervals [CIs]); P value of 0.05 or less was considered
significant. All analyses were conducted using Stata software
version 13 (StataCorp LP).
RESULTS
Sample Characteristics
After excluding 3697 patients with missing data on key
variables (only considering variables with <5% missingness)
the final sample used in complete cases analyses included
58 226 subjects. The average age was 54.1 (±10.0) years
and 1/3 (32.4%) were women. About one-quarter (72.2%)
of the sample was White, compared to 12.8% Hispanic
and 9.3% African American. The average MELD score was
20.9 ± 9.7. Eleven percent (n = 6478) of donors had a history
of DM and 88.9% (n = 51 748) did not.
Table 1 shows recipient pretransplant characteristics by
donor DM status. Recipient characteristics were comparable
among those that received a diabetic versus nondiabetic do-
nor graft.
Table 2 shows donor characteristics by donor DM status.
DM donors were older and more likely to be African American
or Hispanic. A greater proportion of DM donors was obese
and/or suffered from hypertension. DM donors more often
died from anoxia or stroke than trauma.
GF
The median time at risk was 38 months and 11.7% (6797
subjects) experienced GF at any point during the study pe-
riod. Graft survival at 30 days and 1 year posttransplant
was 97.5% (1456 events) and 93.0% (3755 events), respectively.
Table 3 shows HRs for GF within 1 year posttransplant
for DM and CIT. The GF rate was higher for diabetic donor
TABLE 2.
Donor characteristics by donor DM status
Donor diabetes No donor diabetes
Characteristicsa (n = 6478) (n = 51 748) P
Donor Risk Indexb 1.88 ± 0.48 1.57 ± 0.45 <0.001
Age, y 54.0 ± 12.8 40.4 ± 16.9 <0.001
Women 44.7 40.0 <0.001
Race/ethnicity
White 56.7 68.7
African American 25.6 16.2
Other 17.8 15.2 <0.001
BMIc
< 18.5 1.6 3.3
18.5- < 25 22.2 39.1
25 to < 30 31.2 33.6
≥ 30 44.6 23.6 <0.001
Height, cm 170.1 ± 10.4 171.8 ± 10.6 <0.001
Hypertension 79.6 29.3 <0.001
Cause of death
Head trauma 12.0 38.6
Anoxia 28.2 19.7
Stroke 57.5 39.1
Other 2.3 2.6 <0.001
Donation after cardiac death 9.7 11.4 <0.001
Split/partial liver 0.2 1.5 <0.001
Allocation type
Local 68.3 72.8
Regional 23.5 22.5
National 8.3 4.8 <0.001
SRTR 2002-2015 (N = 58 226).
a Mean ± standard deviation or column percentage (variables with missing data may not add up to
100%).
b Donor risk index includes age, race/ethnicity, cause of death, donation after cardiac death, partial/
split liver, height, allocation type, CIT (Feng et al).
c <18.5: underweight; 18.5- < 25: normal; 25- < 30: overweight; ≥30: obese.
TABLE 3.
HRs (95% CIs) for 1-year GF by donor DM status and CIT
Ratea
Unadjusted model,
Crude
Combined model,
adjustedb
Primary
determinants n (%) HR (95% CI)
Prolonged CIT 1503 (8.9) 1.48 1.43
(1.38-1.58) (1.33-1.53)
Not prolonged 2252 (6.2) 1.00 1.00
Donor diabetes 571 (9.7) 1.46 1.22
(1.33-1.59) (1.11-1.34)
No diabetes 3184 (6.7) 1.00 1.00
SRTR 2002-2015 (N = 58 226).
a KM Life table-calculated GF rate, P < 0.001 for difference in survival between groups.
b Adjusted for: recipient age, race/ethnicity, BMI, primary liver diagnosis, hepatitis C, UNOS status 1,
albumin, ascites, medical condition (ICU/hospitalized/home), ventilatory support; donor age, race/
ethnicity, height, cause of death, donation after cardiac death, split/partial liver.
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grafts and for prolonged CIT. Adjustment did not meaning-
fully alter (>10% change in estimate) the HR for risk associ-
ated with CIT. The only risk factor that meaningfully altered
the HR for DM (and remained statistically significant) in the
final models was donor age.
Figure 2 illustrates the (unadjusted) Kaplan-Meier curves
by DM and CIT strata. GF rate was highest in the immediate
postoperative period (days 0-30) for all groups. Graft sur-
vival was lowest for patients that received a diabetic donor
graft with prolonged CIT for up to 3 years posttransplant
and survival functions were significantly different across
strata on log-rank test (P < 0.001).
Table 4 shows theHRs for patients with either or both risk
factors relative to neither. On adjusted analyses, the probabil-
ity of GF within 1 year of transplant was highest for recipi-
ents with a combination of donor DM and prolonged CIT
compared to for recipients of grafts with short CIT from do-
nors without any history of DM (adjusted HR, 1.79; 95%
CI, 1.55-2.06). The unadjusted HRs for subjects with either
factor alone versus neither factor were comparable, but the
HR for donor DM (relative to subjects with neither factor)
declined by about 16% after adjustment.
After multivariable adjustment, 10% of the risk for grafts
with both prolonged CIT and donor DM history was attrib-
utable to interactive effect between CIT and DM, suggestive
of effect measure modification, with a synergy index of 1.30.
In other words, there are likely grafts that would fail in the
presence of both factors that would not otherwise fail without
the added injury from prolonged CIT in a given range of time.
Thus, although the product term (multiplicative interaction)
FIGURE 2. Kaplan-Meier curves: Liver graft survival up to 3 years posttransplant, stratified by donor DM status and short (<8 hours) versus
long (≥8 hours) CIT. SRTR 2002-2010 (N = 33 980).
TABLE 4.
HRs (95% CI) for 1-year GF stratified by donor DM status and
CIT relative to neither risk factor
1-y GF
Ratea Crude Adjustedb
n (%) HR (95% CI)
Prolonged CIT and DM+ 298 (12.6) 2.23 (1.95-2.55) 1.79 (1.55-2.06)
Prolonged CIT, no DM 2401 (8.4) 1.46 (1.36-1.57) 1.42 (1.32-1.53)
DM+, short CIT 905 (8.4) 1.41 (1.26-1.59) 1.19 (1.06-1.35)
DM−, short CIT 6262 (5.9) 1.00 (referent) 1.00 (referent)
a KM Life table-calculated GF rate, P < 0.001 for difference in survival between groups.
b Adjusted for: recipient age, race/ethnicity, BMI, primary liver diagnosis, hepatitis C, UNOS status 1,
albumin, ascites, medical condition (ICU/hospitalized/home), ventilatory support; donor age, race/
ethnicity, height, cause of death, donation after cardiac death, split/partial liver.
TABLE 5.
HRs (95% CIs) for GF for recipients of diabetic donor grafts
and the effect of prolonged CIT
GFa
HR (95% CI)
Days 0-30 Days 31-365
Unadjusted Adjustedb Unadjusted Adjustedc
Donor diabetesd 1.34 1.18 1.46 1.19
(1.10-1.64) (0.96-1.45) (1.26-1.69) (1.02-1.38)
Diabetic donor graft exposed
to prolonged CITe
2.14 1.77 2.29 1.84
(1.71-2.68) (1.40-2.25) (1.94-2.71) (1.55-2.19)
P f 0.35 0.30 0.048 0.047
SRTR 2002-2015 (N = 58 226).
a GF: time from transplant to GF for any reason.
b Adjusted for recipient age, race/ethnicity, primary liver diagnosis, UNOS Status 1, medical condition
(ICU/hospitalized/home), ventilatory support; donor age, race/ethnicity, cause of death, donation after
cardiac death, split liver, allocation type, and donor height.
c Adjusted for: recipient age, race/ethnicity, BMI, primary liver diagnosis, hepatitis C, UNOS status 1,
albumin, ascites, medical condition (ICU/hospitalized/home), ventilatory support; donor age, race/
ethnicity, height, cause of death, donation after cardiac death, split/partial liver.
d HR for recipients of grafts from donors with a history of DM versus grafts from donors with no history
of DM and CIT <8 hours.
e HR for recipients of grafts from donors with a history of DM and prolonged CIT (>8 hours) versus no
history of DM and CIT <8 hours.
f Significance for interaction between donor DM (yes/no) and CIT (yes/no) variables; significant P values
in bold emphasis.
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for CIT and DMwas not significant for overall 1-year GF, we
further subdivided postoperative periods into 0 to 30 days and
31 to 365 days and found that there was a significant syner-
gistic interaction between DMandCIT in the latter postoper-
ative period (Table 5).
DISCUSSION
We used the SRTR database to analyze the extent to which
donor DM modifies the effect of prolonged CIT on the risk
of GF after LT. Our results show that the combination of pro-
longed CIT in a diabetic liver graft has a synergistic effect on
the risk of GF.
Our results are supported by prior literature onGF risk as-
sociated with donor DM and further advance the field by
providing evidence on the interaction between DM and
CIT. A recent study describing 26 645 liver transplant recip-
ients demonstrated that recipients of diabetic donor grafts
have an increased risk of mortality after LT (HR, 1.11;
95% CI, 1.02-1.19).3 In this study, 34.8% of recipients of
grafts from DM donors experience GF compared with
27.8% of recipients that received a non-DM donor graft
(P < 0.001). Another study evaluated 27 033 transplant cases
and showed that donor diabetes was a strong independent
risk factor for GF (HR, 1.20; P = 0.006) in hepatitis C virus
positive transplant recipients.4 Segev et al showed no effect
modification by donor DM on the effects of prolonged CIT.
Our results did not show a significant interaction between
CITand donorDMonoverall 1-yearGF either. The synergis-
tic interaction between DM and CIT was significant in the
latter postoperative period only.9
Type 2 DM is associated with hepatic steatosis, a form of
nonalcoholic fatty liver disease, which can progress to nonal-
coholic steatohepatitis.12,13 Hepatic fat accumulation can re-
sult in liver inflammation through the release of various
cytokines and ultimately cause liver fibrosis.5,14,15 Several
studies have shown that steatotic livers are more likely to ex-
perience IRI, leading to worse clinical outcomes after LT.16,17
Furthermore, the microvascular changes in diabetic donor
grafts, like damage to the sinusoidal lining cells and disruption
of the microvasculature, impair the hepatic microcirculation.
Prolonged CIT can aggravate these microvascular changes
and consequently increase susceptibility to IRI.18-21 Surpris-
ingly, the impact of donor DM status on graft survival was
more pronounced 30 days after LT. This seems to be counter-
intuitive, but can be explained by the fact that donorDM sta-
tus can increase the incidence of acute rejection episodes and
ischemic cholangiopathy. To support this hypothesis, a recent
study on 88 primary LTs demonstrated a significant associa-
tion between donor DM and ischemic-type biliary lesions
with anHR of 9.5 (P = 0.009), suggesting that DMpromotes
chronic changes in the biliary vessels, thereby increasing sus-
ceptibility to IRI.22
There were several limitations to our study. First, it should
be noted that the statistical significance was only marginal.
Second, this is a retrospective analysis and it is impossible
to eliminate allocation biases. As is common in analyses of
large administrative databases, missing data and reliability
of the entered data must be thoroughly evaluated and appro-
priately handled in analyses, and in our study, we did not use
any variables missing more than 5% of values. In addition,
we were also unable to evaluate the direct effect of steatosis
in the donor graft, because biopsy results are not captured
in this database. To address this limitation, we evaluated
BMI as a surrogate of graft steatosis but found it was not as-
sociated with GF after multivariable adjustment and was not
retained in any of our final models. Lastly, we were not able
to assess the impact of the duration of DM, since the SRTR
does not have a variable that quantifies duration of DM. Fu-
ture suggestions would be to investigate whether increasing
GF rates occur with increasing CIT and duration of DM in
a study with a smaller sample size.
Over the last decade more marginal donor organs are be-
ing accepted to increase the shrinking donor organ pool. This
study demonstrates for the first time that liver grafts from a
DM donor are more susceptible to prolonged CIT compared
to nondiabetic donor grafts. The risk of GF within 1 year af-
ter LT is significantly higher in liver grafts from DM donors
with CIT 8 hours or longer compared with diabetic liver
grafts with CIT less than 8 hours. Although the outcomes
of diabetic liver grafts are acceptable, we need to be cognizant
that they are more susceptible to ischemic injury in transit
and IRI intraoperatively.
Expediting allocation of diabetic donor grafts will help to
reduce CITand therefore decrease graft injury. In conclusion,
this study confirmed that donor DM status is an independent
risk factor and contributes synergistically with prolonged
CIT to reduce graft survival.
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